[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112022024523A2 - Uso de 2-hoba para tratar aterosclerose - Google Patents

Uso de 2-hoba para tratar aterosclerose

Info

Publication number
BR112022024523A2
BR112022024523A2 BR112022024523A BR112022024523A BR112022024523A2 BR 112022024523 A2 BR112022024523 A2 BR 112022024523A2 BR 112022024523 A BR112022024523 A BR 112022024523A BR 112022024523 A BR112022024523 A BR 112022024523A BR 112022024523 A2 BR112022024523 A2 BR 112022024523A2
Authority
BR
Brazil
Prior art keywords
hoba
treat atherosclerosis
atherosclerosis
treat
accelerated
Prior art date
Application number
BR112022024523A
Other languages
English (en)
Inventor
F Linton Macrae
S Davies Sean
Boutaud Olivier
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of BR112022024523A2 publication Critical patent/BR112022024523A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Gear Processing (AREA)

Abstract

USO DE 2-HOBA PARA TRATAR ATEROSCLEROSE. Um método de tratamento de aterosclerose acelerada por hipercolesterolemia familiar em um indivíduo em necessidade do mesmo, compreendendo administrar uma quantidade eficaz de um eliminador de dicarbonila.
BR112022024523A 2020-06-01 2021-06-01 Uso de 2-hoba para tratar aterosclerose BR112022024523A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063033127P 2020-06-01 2020-06-01
PCT/US2021/035314 WO2021247620A1 (en) 2020-06-01 2021-06-01 Use of 2-hoba to treat atherosclerosis

Publications (1)

Publication Number Publication Date
BR112022024523A2 true BR112022024523A2 (pt) 2023-01-24

Family

ID=78829877

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024523A BR112022024523A2 (pt) 2020-06-01 2021-06-01 Uso de 2-hoba para tratar aterosclerose

Country Status (9)

Country Link
US (1) US20230364032A1 (pt)
EP (1) EP4157243A4 (pt)
JP (1) JP2023529130A (pt)
CN (1) CN116157118A (pt)
AU (1) AU2021285836A1 (pt)
BR (1) BR112022024523A2 (pt)
CA (1) CA3180792A1 (pt)
MX (1) MX2022015242A (pt)
WO (1) WO2021247620A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2320387A1 (de) * 1973-04-21 1974-10-31 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben
EP1471152A1 (en) * 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
CN102742767B (zh) * 2012-07-17 2013-08-14 德阳市荞老头食品有限公司 一种苦荞蔬菜营养保健饭及其生产工艺
CN104383123A (zh) * 2014-11-14 2015-03-04 程金生 一种金花茶降脂降糖制剂的制备方法
CN106806635A (zh) * 2015-11-29 2017-06-09 陈嗳 一种活血化瘀的苦荞保健口服液及其制备方法
US11389414B2 (en) * 2017-04-27 2022-07-19 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers
CN109601990A (zh) * 2019-01-29 2019-04-12 侯建威 一种微生物发酵抗衰老食品制剂及其制备方法

Also Published As

Publication number Publication date
EP4157243A4 (en) 2024-06-12
US20230364032A1 (en) 2023-11-16
AU2021285836A1 (en) 2023-02-02
CA3180792A1 (en) 2021-12-09
CN116157118A (zh) 2023-05-23
WO2021247620A1 (en) 2021-12-09
JP2023529130A (ja) 2023-07-07
EP4157243A1 (en) 2023-04-05
MX2022015242A (es) 2023-01-11

Similar Documents

Publication Publication Date Title
BR112022017393A2 (pt) Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto
CL2023000095A1 (es) Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
MX379286B (es) INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe).
BR112014028017A2 (pt) composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
MX389242B (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
MX2015010191A (es) Metodos para tratar infecciones microbianas, incluyendo mastitis.
MX2022003193A (es) Tratamiento de encefalopatia asociada al gen syngap1.
BR112022014435A2 (pt) Composição herbicida líquida e métodos para aumentar a atividade herbicida de composições herbicidas líquidas e para tratar o material de propagação de plantas
BR112021018687A2 (pt) Combinação de dose fixa de canabinoides e cogumelos medicinais para prevenção e tratamento de câncer, doenças inflamatórias ou inflamatórias imunomediadas
MX2024003145A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
CO2018004684A2 (es) Métodos para tratar la epilepsia
MX2017011500A (es) Combinaciones y formulaciones de dosis fijas que comprenden ácido 8-hidroxi-2,2,14,14- tetrametilpentadecanodioico (etc1002) y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2022009176A (es) Metodo y composiciones para el tratamiento de infeccion por coronavirus.
AR119043A1 (es) Métodos para acelerar la cicatrización mediante el uso de composiciones cannabinoides
MX389545B (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
MX2019012659A (es) Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido.
BR112022024523A2 (pt) Uso de 2-hoba para tratar aterosclerose